Cover Image
市場調查報告書

Rho相關蛋白激酶2:開發中產品分析

Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365766
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
Back to Top
Rho相關蛋白激酶2:開發中產品分析 Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 59 Pages
簡介

本報告提供以Rho相關蛋白激酶2為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,再加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

Rho相關蛋白激酶2 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Anacor Pharmaceuticals, Inc.
  • Astex Pharmaceuticals, Inc.
  • BioAxone BioSciences, Inc.
  • HitGen LTD
  • Kadmon Corporation, LLC
  • Vertex Pharmaceuticals Incorporated
  • Vichem Chemie Research Ltd.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

目錄
Product Code: GMDHC0217TDB

Summary

Global Markets Direct's, 'Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Pipeline Review, H1 2016', provides in depth analysis on Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1)
  • The report reviews Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) Overview
  • Therapeutics Development
    • Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Products under Development by Stage of Development
    • Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Products under Development by Therapy Area
    • Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Products under Development by Indication
  • Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Products under Development by Companies
  • Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
    • Anacor Pharmaceuticals, Inc.
    • Astex Pharmaceuticals, Inc.
    • BioAxone BioSciences, Inc.
    • HitGen LTD
    • Kadmon Corporation, LLC
    • Vertex Pharmaceuticals Incorporated
    • Vichem Chemie Research Ltd.
  • Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Drug Profiles
    • AN-3485 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-13148 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BA-1049 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KD-025 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KL-00148 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KL-00199 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Rho-associated protein kinase 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit ROCK-2 for Cardiovascular, Ophthalmology and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRN-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VX-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Dormant Projects
  • Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Discontinued Products
  • Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) - Featured News & Press Releases
    • Jun 03, 2016: Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 in Idiopathic Pulmonary Fibrosis
    • Mar 21, 2016: Kadmon Announces Publication of Data Demonstrating the Potential of ROCK2 Inhibition to Treat Chronic Graft-Versus-Host Disease
    • Feb 25, 2016: Kadmon to Present Preclinical Data Demonstrating ROCK2 Signaling as a Key Regulator of T Follicular Helper Cell Function in Autoimmune Conditions
    • Feb 08, 2016: BioAxone BioSciences Announces NIH/SBIR Fast Track Grant to Develop BA-1049 for Treatment of Cerebral Cavernous Malformation/Angioma
    • Jan 11, 2016: Kadmon to Present Preclinical Data Demonstrating the Importance of ROCK2 Signaling in Modulating Immune Response
    • Jun 22, 2015: Kadmon Presents Data Demonstrating Potential of ROCK2 Inhibition to Treat Lupus
    • May 06, 2015: Kadmon Presents Data on Role of ROCK2 Inhibition at AAI Annual Meeting
    • Feb 09, 2015: Kadmon Announces Publication Highlighting Importance of ROCK2 in Autoimmunity
    • Jan 06, 2015: Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 in Psoriasis
    • Dec 11, 2014: Kadmon Corporation's KD025 Named a Top Priority Lupus Treatment Candidate by the Alliance for Lupus Research and the Lupus Research Institute
    • Dec 08, 2014: Kadmon Corporation Presents Preclinical Data on KD025 in Chronic Graft-Versus-Host-Disease at American Society of Hematology Annual Meeting
    • Nov 10, 2014: Kadmon Researchers Define Importance of ROCK2 Signaling Pathway in Human Autoimmune Response
    • May 05, 2014: Kadmon Corporation Presents Results of KD025 Preclinical and Clinical Studies at AAI Annual Meeting
    • Apr 08, 2014: Kadmon Corporation Announces the Initiation of KD025 Phase 2 Program in Psoriasis
    • Mar 27, 2014: Kadmon Corporation Presents Results at the 9th International Congress on Autoimmunity Demonstrating the Effects of KD025 on Immune Homeostasis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Anacor Pharmaceuticals, Inc., H1 2016
  • Pipeline by Astex Pharmaceuticals, Inc., H1 2016
  • Pipeline by BioAxone BioSciences, Inc., H1 2016
  • Pipeline by HitGen LTD, H1 2016
  • Pipeline by Kadmon Corporation, LLC, H1 2016
  • Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016
  • Pipeline by Vichem Chemie Research Ltd., H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top